UBS Group
NSPR icon

UBS Group’s InspireMD NSPR Stock Holding History

UBS Group’s Portfolio NSPR Stock Details NSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.42K Buy
2,098
+2,066
+6,456% +$3.52K ﹤0.01% 9089
2025
Q4 		$57 Buy
+32
New +$67 ﹤0.01% 10257
2025
Q3 		– Sell
-124,638
Closed -$283K – 10736
2025
Q2 		$283K Buy
+124,638
New +$311K ﹤0.01% 6482
2024
Q4 		– Sell
-2,363
Closed -$6.33K – 10246
2024
Q3 		$6.33K Buy
+2,363
New +$6.45K ﹤0.01% 7980
2024
Q1 		– Sell
-1,168
Closed -$3.28K – 9801
2023
Q4 		$3.28K Buy
+1,168
New +$3.36K ﹤0.01% 7994
2023
Q3 		– Sell
-184
Closed -$462 – 9810
2023
Q2 		$462 Buy
184
+81
+79% +$129 ﹤0.01% 8220
2023
Q1 		$116 Sell
103
-1,040
-91% -$1.22K ﹤0.01% 9215
2022
Q4 		$983 Sell
1,143
-5,083
-82% -$5.72K ﹤0.01% 10012
2022
Q3 		$9K Buy
6,226
+1,718
+38% +$3.13K ﹤0.01% 8588
2022
Q2 		$9K Buy
4,508
+2,325
+107% +$5.51K ﹤0.01% 8160
2022
Q1 		$7K Buy
+2,183
New +$6.05K ﹤0.01% 8831
2020
Q4 		– Sell
-930
Closed -$4K – 8625
2020
Q3 		$4K Buy
930
+731
+367% +$4.64K ﹤0.01% 7422
2020
Q2 		$1K Buy
199
+34
+21% +$345 ﹤0.01% 7784
2020
Q1 		$2K Sell
165
-96
-37% -$1.39K ﹤0.01% 7623
2019
Q4 		$4K Buy
261
+232
+800% +$3.67K ﹤0.01% 7670
2019
Q3 		$1K Buy
+29
New +$1.17K ﹤0.01% 7846
2019
Q2 		– Sell
-93
Closed -$10K – 8060
2019
Q1 		$10K Sell
93
-23
-20% -$2.97K ﹤0.01% 6814
2018
Q4 		$14K Buy
+116
New +$18.4K ﹤0.01% 7044
2018
Q3 		– Sell
-27
Closed -$4.29K – 8162
2018
Q2 		$5K Buy
+27
New +$22.9K ﹤0.01% 7475
2018
Q1 		– Sell
-3
Closed -$10.3K – 8054
2017
Q4 		$10K Buy
+3
New +$24.8K ﹤0.01% 7027
2017
Q3 		– Hold
0
– – – 7581
2017
Q2 		– Hold
0
– – – 7505
2017
Q1 		– Hold
0
– – – 7294
2016
Q4 		– Hold
0
– – – 6815
2016
Q3 		– Hold
0
– – – 7292
2016
Q2 		– Hold
0
– – – 7887
2016
Q1 		– Hold
0
– – – 7440
2015
Q4 		– Hold
0
– – – 7177
2015
Q3 		– Hold
0
– – – 7605
2015
Q2 		– Hold
0
– – – 7790
2015
Q1 		– Hold
0
– – – 5964
2014
Q4 		– Hold
0
– – – 7675

Other funds holding NSPR

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

UBS Group's NSPR Position: Q1 2026 in Review

UBS Group increased its InspireMD (NSPR) stake by 6,456% in Q1 2026, buying an estimated $3.52K and bringing the position to 2,098 shares worth $3.42K. The position accounts for ﹤0.01% of the portfolio, ranked #9089.

UBS Group first reported a position in NSPR in Q4 2017 and has held it in 20 quarters since. The position peaked at $283K in Q2 2025. 35 funds tracked by Wall St. Rank hold NSPR as of Q1 2026.

  • UBS Group held 2,098 shares of InspireMD worth $3.42K as of Q1 2026.
  • UBS Group bought 2,066 InspireMD shares in Q1 2026, an estimated $3.52K.
  • InspireMD made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9089 holding.
  • UBS Group first reported a position in InspireMD in Q4 2017 and has held it in 20 quarters since.
  • UBS Group's InspireMD position peaked at $283K in Q2 2025.
  • 35 funds tracked by Wall St. Rank held InspireMD as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.